Fig. 1.

(A) Visual demonstration of device priming, where priming buffer (green) injected in the priming inlet arrives at each inlet port and the outlet port simultaneously. (B) Blood added to the inlet wells displaces priming fluid when negative pressure is applied at the outlet. (C) Fluorescence images for AF488-conjugated anti-CD61 (green) and AF594-conjugated human fibrinogen (red) for clots formed under flow. (D) Dose response in fibrin fluorescence intensity for addition of apixaban to whole blood ex vivo, and represented as an IC50 curve (E). (F) Fibrin FI for whole blood perfused as collected, with the addition of 200 nM apixaban ex vivo, and with both apixaban and an equimolar ratio of Andexanet Alfa reversal agent, where reversal agent restores the FI to uninhibited levels. All data obtained with human blood from consenting adults under IRB approval (University of Pennsylvania).